Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with implantable cardioverter-defibrillators often receive adjunctive antiarrhythmic therapy to prevent frequent shocks. We tested the efficacy and safety of sotalol, a beta-blocker with class III antiarrhythmic effects, for this purpose. METHODS: In a multicenter trial, patients were stratified according to left ventricular ejection fraction (< or =0.30 or >0.30), randomly assigned to double-blind treatment with 160 to 320 mg of sotalol per day (151 patients) or matching placebo (151 patients), and followed for 12 months. Kaplan-Meier analyses of the time to an event were performed. Three end points were used: the delivery of a first shock for any reason or death from any cause, the first appropriate shock for a ventricular arrhythmia or death from any cause, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause. RESULTS: Compliance with double-blind treatment was similar in the two groups. There were seven deaths in the placebo group and four in the sotalol group. As compared with placebo, treatment with sotalol was associated with a lower risk of death from any cause or the delivery of a first shock for any reason (reduction in risk, 48 percent; P<0.001 by the log-rank test), death from any cause or the delivery of a first appropriate shock (reduction in risk, 44 percent; P=0.007), or death from any cause or the delivery of a first inappropriate shock (reduction in risk, 64 percent; P=0.004). Sotalol also reduced the mean (+/-SD) frequency of shocks due to any cause (1.43+/-3.53 shocks per year, as compared with 3.89+/-10.65 in the placebo group; P=0.008). In the sotalol group, the reduction in the risk of death from any cause or the delivery of a first shock for any reason did not differ significantly between patients with ejection fractions of more than 0.30 and those with ejection fractions of 0.30 or less. CONCLUSIONS: Oral sotalol was safe and efficacious in reducing the risk of death or the delivery of a first defibrillator shock whether or not ventricular function was depressed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies, from 7.5% of primary prevention patients 22 to 48% of those with a history of ventricular arrhythmia 23 received a shock for any reason in a year.”
From Managing with pacemakers and implantable cardioverter defibrillators (2013) · cites this paper as [23]
In the citing paper
“Many studies 26 have demonstrated that pharmacological interventions such as sotalol 23 and amiodarone 27 can decrease shocks”
From Managing with pacemakers and implantable cardioverter defibrillators (2013) · cites this paper as [23]
Citations
Cites
Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., Levine, J. H., Saksena, S., Waldo, A. L., Wilber, D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352601 · Cited by 4,165
Self-citationEcht, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
(1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372202 · Cited by 3,232
Julian, D., Camm, A., Frangin, G., Janse, M., Munoz, A., Schwartz, P., & Simon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09145-3 · Cited by 1,112
Cairns, J. A., Connolly, S. J., Roberts, R., & Gent, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)08171-8 · Cited by 957
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias
Mason, J. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290702 · Cited by 462
Heidenreich, P. A., Lee, T. T., & Massie, B. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00104-6 · Cited by 361
Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study)
The CASCADE Investigators (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90673-z · Cited by 308
Wood, A. J. J., Hohnloser, S. H., & Woosley, R. L. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407073310108 · Cited by 168
Self-citation
Cited by
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
Zeppenfeld, K., Tfelt-Hansen, J., de Riva, M., Winkel, B. G., Behr, E. R., Blom, N. A., Charron, P., Corrado, D., Dagres, N., de Chillou, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac262 · Cited by 3,140
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Myerburg, R. J., Quinones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,973
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.054 · Cited by 1,854
(2015) · Europace · doi:10.1093/europace/euv319 · Cited by 1,592
Metadata
- Authors
- Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., & Prystowsky, E. N.
- Affiliations
- Goethe University Frankfurt (DE)
- St Vincent Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-06-17
- Volume
- 340
- Issue
- 24
- Pages
- 1855-1862
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2002864523
- Semantic Scholar
- 56db8c4a185d008df7710e91a46cf46d3218d959
- Cited by
- 422
- References
- 26
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 10 · 2020: 8 · 2019: 17 · 2018: 13 · 2017: 26 · 2016: 17 · 2015: 15 · 2014: 10 · 2013: 22 · 2012: 10
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- sotalol, implantable cardioverter-defibrillator, inappropriate shocks, antiarrhythmic therapy, beta-blockers, class III antiarrhythmic agents, left ventricular ejection fraction, ventricular arrhythmias, mortality, shock prevention
- MeSH terms
- Adrenergic beta-Antagonists, Adult, Aged, Anti-Arrhythmia Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Sotalol, Stroke Volume, Tachycardia, Survival Analysis, Chemotherapy, Adjuvant, Defibrillators, Implantable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. https://app.cochat.ai/papers/10.1056/nejm199906173402402
- The paper
- Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., & Prystowsky, E. N. (1999). Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. New England Journal of Medicine. https://doi.org/10.1056/nejm199906173402402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.